Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1643 1646 1674
This examiner grants 72% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17241935 | DRUG DELIVERY COMPOSITIONS AND USES THEREOF | Non-Final OA | Dana-Farber Cancer Institute, Inc. |
| 18246512 | ANTI-INFLAMMATORY CYTOKINES AND METHODS OF USE | Non-Final OA | THE UNIVERSITY OF CHICAGO |
| 18235679 | COMBINATION THERAPIES FOR INHIBITION OF TTK PROTEIN KINASE | Non-Final OA | UNIVERSITY HEALTH NETWORK |
| 18265341 | HETERODIMERIC IGA FC CONSTRUCTS AND METHODS OF USE THEREOF | Non-Final OA | Zymeworks BC Inc. |
| 18297076 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | Non-Final OA | Immatics Biotechnologies GmbH |
| 18265781 | BISPECIFIC ANTIBODIES BINDING TO CD7 AND CD33 | Non-Final OA | BIVICTRIX LIMITED |
| 18265783 | NOVEL METHODS OF THERAPY | Non-Final OA | BIVICTRIX LIMITED |
| 18018156 | USE OF EPIDERMAL GROWTH FACTOR DEPLETING AGENTS IN THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE | Non-Final OA | Centro de Inmunología Molecular |
| 18305165 | ILT7 BINDING MOLECULES AND METHODS OF USING THE SAME | Non-Final OA | Viela Bio, Inc. |
| 18299343 | USE OF IL-22 DIMER IN MANUFACTURE OF A MEDICAMENT FOR INTRAVENOUS ADMINISTRATION | Non-Final OA | Evive Biotechnology (Shanghai) Ltd |
| 17758279 | IMMUNOGENIC CONJUGATE INTENDED TO INDUCE AN IMMUNE RESPONSE DIRECTED AGAINST INTERLEUKIN-6 | Non-Final OA | PEPTINOV |
| 18004631 | COMPOSITIONS AND METHODS USEFUL FOR THE PREVENTION AND/OR TREATMENT OF DISEASE IN MAMMALS | Final Rejection | VIRO-GEN (PTY) LTD |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy